OraSure Technologies Supports Global and Domestic Rapid HIV Testing Initiatives for World AIDS Day
02 December 2008 - 12:46AM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics, today announced its support of rapid HIV testing
initiatives taking place in more than 20 states in the U.S. and
several countries globally, in recognition of World AIDS Day,
commemorated annually on December 1st. OraSure�s support of these
initiatives includes the production of HIV testing promotional
materials, complimentary OraQuick ADVANCE� Rapid HIV-1/2 Antibody
test kits to be used in conjunction with World AIDS Day, and any
necessary product training for newly launched sites. In conjunction
with World AIDS Day, AIDS Healthcare Foundation (AHF) is launching
a program to test 1 million people around the world in the week
leading up to World AIDS Day (www.onemilliontests.org). In support
of this program, OraSure has provided a quantity of rapid oral
fluid tests in countries where such testing does not currently
exist. Now in its 20th year, World AIDS Day is an international day
of observance to honor those who have died from AIDS, as well as
increase awareness of the disease in hopes of fighting the spread
of HIV. �We are pleased to be part of such an important day that
brings together people all over the world in the fight against
HIV/AIDS,� said Douglas Michels, President and CEO of OraSure
Technologies. �OraSure is actively encouraging individuals to learn
their HIV status through routine HIV testing � a critical step that
enables those who are infected with the virus to receive immediate
care and reduce the spread of this disease.� Committed to working
in partnership with local, national and international agencies to
fight against HIV/AIDS, OraSure is actively supporting testing and
education campaigns both domestically and abroad that urge people
to learn their HIV status. In the U.S., OraSure is supporting
testing events in 20 states and several major cities including
Chicago, Philadelphia, and Miami, where clinics and public health
sites are implementing rapid oral fluid HIV testing programs with
OraQuick ADVANCE�. According to UNAIDS, 33 million people worldwide
were living with HIV in 2007. Worldwide, most people living with
HIV are unaware that they are infected. The OraQuick ADVANCE� Rapid
HIV-1/2 Antibody Test, manufactured and sold by OraSure
Technologies, is the first and only U.S. Food and Drug
Administration ("FDA") approved and CLIA (Clinical Laboratory
Improvements Amendments Act of 1988) waived rapid point-of-care
test that can detect antibodies to both HIV-1 and HIV-2 in 20
minutes, using oral fluid, finger-stick or venipuncture whole blood
and plasma specimens. About OraSure Technologies OraSure
Technologies develops, manufactures and markets oral fluid specimen
collection devices using proprietary oral fluid technologies,
diagnostic products including immunoassays and other in vitro
diagnostic tests, and other medical devices. These products are
sold in the United States as well as internationally to various
clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, distributors,
government agencies, physicians� offices, and commercial and
industrial entities. OraSure Technologies is the leading supplier
of oral-fluid collection devices and assays to the life insurance
industry and public health markets for the detection of antibodies
to HIV. In addition, the Company supplies oral-fluid testing
solutions for drugs of abuse testing. For more information on the
Company, please go to www.orasure.com.
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2023 to Jul 2024